Status:
COMPLETED
Safety of Single Rising Doses and Relative Bioavailability of BI 691751
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
To investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of single rising doses of BI 691751 in healthy male subjects (part I). To investigate the relative bioavailability of ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy male subjects
- Subjects must be able to understand and comply with study requirements
- Age from 18 to 55 years
- BMI range: from 18.5 to 29.9 kg/m2
- Known genotype as specified in the study protocol
- Exclusion criteria:
- 1\. Any relevant deviation from healthy conditions
Exclusion
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT01843972
Start Date
April 1 2013
End Date
November 1 2013
Last Update
June 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1334.1.1 Boehringer Ingelheim Investigational Site
Biberach, Germany